Another paradigmatic example is the initial good response to specific inhibitors in melanomas harboring the BRAFV600E mutation, compared to the protumor effect of the same inhibitors in colon adenocarcinomas carrying similar BRAF mutations (Prahallad et al., 2012; Sclafani et al., 2013). This evidence concerns the gene BRAF and colon adenocarcinoma.